Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine

The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Studieoversikt

Detaljert beskrivelse

Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.

Isobaric chloroprocaine is a local anesthetic increasingly used for spinal anesthesia to reduce the duration of sensory and motor blocks compared to bupivacaine, allowing for faster postoperative recovery. However, certain medications used during surgery may possibly influence the duration of spinal anesthesia. Among these is dexamethasone, a drug belonging to the corticosteroid family. Dexamethasone is a well-known and commonly used medication in anesthesia to prevent postoperative nausea and vomiting. It is also used by anesthesiologists to reduce pain in the context of fast functional recovery after surgery. The safety of single-dose intravenous dexamethasone is therefore established in the context of anesthesia for several types of surgery.

Medical literature demonstrates that dexamethasone can prolong the effect of certain local anesthetics when administered intravenously or perineurally (near the nerves), and sometimes has no effect on the duration of local anesthetics administered for spinal anesthesia. Currently, no information is available in the literature on the effect of intravenous dexamethasone on the duration of a spinal anesthesia with isobaric chloroprocaine.

This study aims to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Quebec
      • Montreal, Quebec, Canada, H2X 3E4

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age between 18 and 90 years old
  • ASA status I to III inclusively
  • Planned lower body surgery under spinal anesthesia with chloroprocaine
  • Signed informed consent form

Exclusion Criteria:

  • Contraindication to spinal anesthesia: infection at the puncture site, congenital or acquired coagulopathy
  • Preexisting neuropathy or nerve block that could interfere with study assessments
  • Allergy or hypersensitivity to local anesthetics, dexamethasone, or other medications used in the study
  • Preoperative use of corticosteroids
  • Patient refusal
  • Inability to consent
  • Language barrier, psychiatric, physical, or mental condition making sensory and motor blocks assessment impossible despite prior instruction
  • Administration of any intrathecal adjuvant (fentanyl, morphine, clonidine, dexmedetomidine, epinephrine, or others) along with chloroprocaine
  • Perioperative intravenous dexmedetomidine administration
  • Conversion to general anesthesia
  • Impossible post-anesthesia care unit assessment: patient still intubated / transfer to intensive care unit, research team constraints, or other reasons
  • Assessment in the recovery room impossible: medical condition (shock, delirium, major agitation, altered state of consciousness, or other), transfer to the intensive care unit, research team constraints, or other

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Intravenous dexamethasone

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia with chloprocaine

Andre navn:
  • Dekadron
Placebo komparator: Intravenous normal saline

During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant.

Administration of a single-dose of Normal saline during spinal anesthesia with chloprocaine

Andre navn:
  • Placebo

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Regression of sensory block by 2 dermatomes
Tidsramme: At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Loss of pinprick sensation by Von Frey filaments from the injection of chloroprocaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level

At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Duration of motor block
Tidsramme: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Using the Bromage scale from the time of injection of chloroprocaine for spinal anesthesia until complete recovery of motor block

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Time until the first observable regression of the motor block
Tidsramme: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery

Time between the local anesthesic injection and the first measurable regression of the motor block measured using the Bromage scale.

At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
Onset of sensory block
Tidsramme: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation

Up to 30 minutes following spinal anesthesia
Onset of motor block
Tidsramme: Up to 30 minutes following spinal anesthesia

Time from injection of chloroprocaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale

Up to 30 minutes following spinal anesthesia
Quality of motor block
Tidsramme: Up to 30 minutes following spinal anesthesia

Maximal Bromage score The Bromage scale is a standardized tool used in neuraxial anesthesia to quantify motor block intensity in the lower extremities. It assesses a patient's ability to move their legs and feet. A scale of 0 to 3 is used: 0 - Full movement, 1- Partial block, 2 - Nearly complete block and 3 - Complete block.

The maximal Bromage score reflects the deepest level of lower-limb motor block, with higher scores indicating stronger motor impairment and therefore a denser motor block.

Up to 30 minutes following spinal anesthesia
Opioid consumption
Tidsramme: At recovery room discharge, approximately one hour after the end of surgery

Total dose of opioids

At recovery room discharge, approximately one hour after the end of surgery
Antiemetic consumption
Tidsramme: At recovery room discharge, approximately one hour after the end of surgery

Total dose of antiemetics

At recovery room discharge, approximately one hour after the end of surgery
Incidence of hypotension
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Systolic blood pressure lower than 90 mm Hg

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of bradycardia
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Heart rate slower than 50 beats per minute

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of nausea
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of nausea reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of vomiting
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of retching or vomiting reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of itching
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of itching reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of urinary retention
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of urinary retention reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of shivering
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of shivering reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Incidence of headache
Tidsramme: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery

Any episode of headache reported by the patient or nursing team

From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
Quality of postoperative recovery
Tidsramme: At 24 hours after the surgery

QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 150 (optimal outcome).

At 24 hours after the surgery
Intensity of nausea/vomiting
Tidsramme: At 24 hours after surgery

Pre-established analysis of nausea/vomiting intensity at 24 hours based on the QoR-15 question. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Pain intensity
Tidsramme: At 24 hours after surgery

Pre-established analysis of pain intensity at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Quality of sleep
Tidsramme: At 24 hours after surgery

Pre-established analysis of sleep quality at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score).

At 24 hours after surgery
Surgeon's satisfaction towards spinal anesthesia
Tidsramme: At the end of surgery, on the day of randomization

Unsatisfied or satisfied

At the end of surgery, on the day of randomization

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Stephan Williams, MD, PhD, Santé Québec - CHUM

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. november 2027

Studiet fullført (Antatt)

1. november 2027

Datoer for studieregistrering

Først innsendt

18. september 2026

Først innsendt som oppfylte QC-kriteriene

18. september 2026

Først lagt ut (Faktiske)

23. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. oktober 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere